Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
80% of the finalists for the ‘Most Valuable Patient Initiative’ Categoryof the 2015 eyeforpharma Philadelphia Awards are focussing on education as a means of engaging with andimproving the lives of patients.
eyeforpharma, London (January, 19, 2015): According to LEO Pharma, Ipsen and Grünenthaldriving patient-centric leadership has become priority as the patient voice shapes the future for the pharmaceutical industry.
This appointment will allow him to drive developments at CiToxLAB’s European and North American sites in the area of preclinical and clinical biomarkers, which is currently experiencing strong growth
Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma. Asserting that harmonisation would be the only way for market access to make a step improvement, Bergström explained that it was in everyone’s interests, not just those of pharmaceutical companies.
US-based Eli Lilly and Company has completed the acquisition of Novartis Animal Health for $5.4bn.
TxCell and Ferring collaboration with lead product Ovasave(R) to receive additional development expertise from Trizell
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today a further enhancement to the development of its lead product Ovasave(R) for the treatment of Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis. The collaboration, option, development and license agreement between TxCell and Ferring International Center SA (Ferring) has been assigned to Trizell Holding SA (Trizell), an affiliate member of the Dr Frederik Paulsen Foundation.
Janssen Healthcare Innovation’s Care4Today programme is set to take two of the highest honours at the 2015 eyeforpharma Barcelona Awards as the shortlist was today announced.
Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive digital resources or mobile applications to engage with the patient; a tell-tale sign of the dominance of patient engagement as a focus for pharma right now. The list of finalists, announced today, includes Abbvie, AstraZeneca, Bayer, Janssen Healthcare Innovation and Novartis all vying for the ultimate accolade in pharma; to be crowned ‘most valuable’ to their patients.
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Page 1 of 67